Alivus Life Sciences Ltd

- The transcript does not mention any current or planned fundraising through debt or equity. - Alivus Life Sciences Limited remains a net debt-free company as of September 30, 2025. - The company has cash and cash equivalents, including short-term investments, amounting to INR 653 crores. - They have more than INR 650 crores of cash on hand and prefer to reinvest this cash back into the business for growth and capex needs. - Capex projects are funded through internal accruals and better credit from suppliers, avoiding the need for external debt or equity raising at this time. - The company is evaluating capital deployment opportunities but no specific plans for raising debt or equity were disclosed for the near term.

- Capex for H1 FY '26 was INR113 crores; Q2 alone INR61 crores. - Board-approved capex budget for FY '26 is INR600 crores, including INR190 crores carryover from FY '25. - Capex slowed in H1; R&D center spend is half the planned INR90-100 crores for FY '26, causing some delay. - Planned capex spend for H2 FY '26 is around INR250 crores. - Capacity expansion projects at Solapur, Ankleshwar, and Dahej are progressing well and on track. - Ankleshwar projects to be operational by June 2026 (Q2 FY '27). - Dahej projects expected operational from Q1 FY '27. - Solapur facility targeted to start from April next year. - Strategic focus on own R&D center with expandable space to support growth for next 5 years. - Company holds INR650+ crores in cash; evaluating inorganic and other capital deployment opportunities but currently prioritizing organic growth.

- The company expects steady growth in FY '26, driven by strong demand momentum and improved visibility for the second half. - Non-GPL business grew by ~40% driven by successful new product launches; outlook remains strong. - Anticipated rebound in GPL business in the second half of FY '26. - CDMO segment expected to show a meaningful turnaround in H2 FY '26 with five projects ramping up. - Japan market to see new commercial launches, with 8-9 products going commercial, up from 4 previously, expecting 4 new molecules launched annually. - Broad-based growth expected from emerging markets, LATAM, Japan, Europe, and India. - Overall capex and capacity expansions (Solapur, Ankleshwar, Dahej) on track to support growth. - Guidance reaffirmed for high single-digit revenue growth in FY '26.

- Alivus Life Sciences expects steady growth in FY '26 driven by strong demand momentum and improved visibility for the second half. - High single-digit revenue growth is reaffirmed for FY '26, fueled by broad-based external sales growth, turnaround in GPL business, and ramp-up of CDMO projects. - CDMO business is anticipated to rebound in the second half with new projects and existing project ramp-up. - Profitability expected to sustain margins around 30% despite absence of PLI benefits, supported by new launches and operational efficiencies. - EBITDA and PAT margins showed significant year-on-year improvement, indicating profitability momentum. - Working capital stable, with receivable days around 148 days, limited scope to significantly reduce working capital days. - Capex spend reduced in H1 but projects remain on track to support growth. - Pipeline strong with 586 DMF/CEP filings and 26 high-potent APIs under development.

The transcript provided does not explicitly mention the current or expected order book or pending orders for Alivus Life Sciences Limited. However, some related insights are: - The CDMO business has a healthy pipeline with 586 DMF and CEP filings globally as of September 30, 2025. - There are 26 high-potent API products in the active development grid, representing a $66 billion addressable market. - The company is confident of a meaningful turnaround in the CDMO segment in H2 FY '26 due to new projects and ramp-up of existing projects. - The outlook for GPL business is positive with expected improvement in the second half of FY '26. - New product launches and a strong pipeline are driving growth expectations. - Capacities at Solapur, Ankleshwar, and Dahej are expanding to support business growth. No direct figures or detailed order backlog values are disclosed in the transcript.